Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Illumina appointed Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky currently serves as Chief Scientific and Product Officer of Eli Lilly and Company, bringing extensive experience in drug discovery and clinical development.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.